Waites G M, Wang C, Griffin P D
Clinic for Infertility and Gynaecological Endocrinology, University Hospital of Geneva, Switzerland.
Int J Androl. 1998 Feb;21(1):8-12. doi: 10.1046/j.1365-2605.1998.00092.x.
Following clinical trials conducted in China in the 1970s, gossypol was proposed as a drug for male contraceptive use. This review summarizes the extensive investigations on formal animal toxicology and on the recovery of fertility in men after stopping gossypol treatment which led to the decision by the Special Programme of Research, Development and Research Training in Human Reproduction (HRP) at the World Health Organization (WHO), that gossypol would not be acceptable as an antifertility drug. It is concluded that the assessment of gossypol reinforces the mandatory requirement that future contraceptive drugs must be developed by the established routes of appropriate animal toxicology and phased clinical studies.
在20世纪70年代于中国开展临床试验之后，棉酚被提议用作男性避孕药物。本综述总结了有关正式动物毒理学以及男性停止棉酚治疗后生育力恢复情况的广泛研究，这些研究促使世界卫生组织（WHO）人类生殖研究、发展与研究培训特别规划署（HRP）做出决定，即棉酚不能作为一种抗生育药物被接受。得出的结论是，对棉酚的评估强化了一项强制性要求，即未来的避孕药物必须通过适当的动物毒理学既定途径和分阶段的临床研究来开发。
